Navigation Links
Sinovac Requests Extension for Annual Shareholders Meeting
Date:12/13/2007

BEIJING, Dec. 13 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that it has notified the Listing Qualifications Department at the American Stock Exchange that the Company will defer its 2007 annual stockholders meeting to no later than April 30, 2008.

The Company originally scheduled its 2007 annual stockholders meeting in August 2007. The meeting was postponed because the Company could not form the necessary quorum, which is 50% of the outstanding shares based on the Company's by-laws. The Company does not believe that it will be able to form the necessary quorum to hold the 2007 annual meeting by year-end, and it is continuing to evaluate different options as an Antigua corporation and a foreign private issuer.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B) and Anflu(TM) (influenza). Sinovac is currently developing human vaccines against the H5N1 strain of pandemic influenza, and Japanese encephalitis. Additional information about Sinovac is available on its website, http://www.sinovac.com. To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward- looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-0088 Ext. 871

Fax: +86-10-6296-6910

Email: info@sinovac.com

Investors/Media:

Stephanie Carrington/Janine McCargo

The Ruth Group

Tel: +1-646-536-7017/7033

Email: scarrington@theruthgroup.com/jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
3. Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products
4. Sysmex America Awarded MedAssets Supply Chain Systems Hematology Contract Extension
5. AMDL Announces Filing of Extension on Third Quarter 2007 Form 10-QSB
6. Annual General Meeting ("AGM") and Extraordinary General Meeting ("EGM") Notices Posted to Shareholders
7. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
8. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
9. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Annual Healthcare Conference
10. FDA and Conformia Deliver Joint Presentation to Annual Regulatory and Compliance Symposium at Harvard
11. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one ... of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has ... add Target to its list of well-respected retailers. This list includes such fine ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
Breaking Biology Technology:
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting ... are setting a new clinical standard in telehealth thanks ... By leveraging the higi platform, IMPOWER patients can routinely ... pulse and body mass index, and, when they opt ... and convenient visit to a local retail location at ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):